Finance

Lists
Why is DUL down 2,42%?
Dive Deeper
DUL:ETR
Alnylam Pharmaceuticals, Inc.
€193,90
-2,42%
(-4,80) 1D
5 Okt., 17:35:35 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for DUL...
Open
€198,35
High
€198,35
Low
€193,90
Mkt. cap
29,59 mjd
Avg. vol.
37,00
Volume
41,00
52-wk high
€417,40
52-wk low
€177,10
No. of employees
2 k
Open
€198,35
High
€198,35
Low
€193,90
Mkt. cap
29,59 mjd
Avg. vol.
37,00
Volume
41,00
52-wk high
€417,40
52-wk low
€177,10
No. of employees
2 k
News stories
From web sources and news partners
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEO-
Employees2,5 k
Founded14 Jun. 2002
Headquarters-
Sector-
Websitealnylam.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,25 mjd
1,10 mjd
1,17 mjd
1,29 mjd
Cost of goods sold
200,15 m
267,72 m
211,12 m
298,45 m
Cost of revenue
200,15 m
267,72 m
211,12 m
298,45 m
Research and development expenses
358,81 m
372,22 m
364,87 m
413,13 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
322,08 m
325,37 m
322,55 m
347,92 m
Operating expense
680,89 m
697,59 m
687,42 m
761,06 m
Total operating expenses
881,04 m
965,32 m
898,54 m
1,06 mjd
Operating income
367,98 m
131,72 m
268,64 m
231,44 m
Other non operating income
-74,15 m
92,98 m
-4,30 m
273,00 k
EBT including unusual items
238,97 m
161,14 m
221,65 m
177,81 m
EBT excluding unusual items
278,12 m
121,99 m
221,65 m
177,81 m
Income tax expense
-12,12 m
-25,28 m
15,66 m
13,31 m
Effective tax rate
-5,07%
-15,69%
7,07%
7,49%
Other operating expenses
-
-
-
-
Net income
251,08 m
186,42 m
205,99 m
164,49 m
Net profit margin
20,10%
16,99%
17,65%
12,74%
Earnings per share
2,90
1,25
1,99
1,84
Interest and investment income
28,68 m
26,63 m
26,60 m
28,14 m
Interest expense
-44,40 m
-129,34 m
-69,29 m
-82,05 m
Net interest expenses
-15,72 m
-102,71 m
-42,69 m
-53,91 m
Depreciation and amortization charges
-
-
-
-
EBITDA
381,78 m
145,22 m
282,19 m
245,34 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme